PL2424870T3 - Środki terapeutyczne 713 - Google Patents
Środki terapeutyczne 713Info
- Publication number
- PL2424870T3 PL2424870T3 PL10718670T PL10718670T PL2424870T3 PL 2424870 T3 PL2424870 T3 PL 2424870T3 PL 10718670 T PL10718670 T PL 10718670T PL 10718670 T PL10718670 T PL 10718670T PL 2424870 T3 PL2424870 T3 PL 2424870T3
- Authority
- PL
- Poland
- Prior art keywords
- therapeutic agents
- therapeutic
- agents
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17463009P | 2009-05-01 | 2009-05-01 | |
| PCT/GB2010/050698 WO2010125390A1 (en) | 2009-05-01 | 2010-04-29 | Therapeutic agents 713 |
| EP10718670.2A EP2424870B1 (en) | 2009-05-01 | 2010-04-29 | Therapeutic agents 713 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2424870T3 true PL2424870T3 (pl) | 2016-05-31 |
Family
ID=42290768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10718670T PL2424870T3 (pl) | 2009-05-01 | 2010-04-29 | Środki terapeutyczne 713 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8110566B2 (pl) |
| EP (1) | EP2424870B1 (pl) |
| JP (1) | JP5763052B2 (pl) |
| KR (1) | KR20120023044A (pl) |
| CN (2) | CN103936751A (pl) |
| AR (1) | AR076516A1 (pl) |
| AU (1) | AU2010243341B2 (pl) |
| BR (1) | BRPI1014387A2 (pl) |
| CA (1) | CA2759230A1 (pl) |
| DK (1) | DK2424870T3 (pl) |
| ES (1) | ES2562831T3 (pl) |
| HR (1) | HRP20160128T1 (pl) |
| HU (1) | HUE026856T2 (pl) |
| MX (1) | MX2011011618A (pl) |
| PL (1) | PL2424870T3 (pl) |
| PT (1) | PT2424870E (pl) |
| RU (1) | RU2526055C2 (pl) |
| SA (1) | SA110310332B1 (pl) |
| SI (1) | SI2424870T1 (pl) |
| SM (1) | SMT201600041B (pl) |
| TW (1) | TW201100433A (pl) |
| UY (1) | UY32593A (pl) |
| WO (1) | WO2010125390A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008049864A1 (en) * | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| AU2011275547B2 (en) | 2010-07-06 | 2015-10-29 | Astrazeneca Ab | Therapeutic agents 976 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| HU230880B1 (hu) | 2015-04-15 | 2018-11-29 | Richter Gedeon Nyrt | Indol származékok |
| KR102866499B1 (ko) | 2019-03-15 | 2025-10-02 | 더 제너럴 하스피탈 코포레이션 | Tead 전사인자의 신규한 소분자 저해제 |
| EP4076527A4 (en) * | 2020-01-10 | 2024-05-15 | Consynance Therapeutics, Inc. | Therapeutic combinations of drugs and methods of using them |
| HUP2200222A1 (hu) | 2022-06-17 | 2023-12-28 | Richter Gedeon Nyrt | MCHR1 antagonisták a Prader-Willi szindróma kezelésére |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1625554A (zh) * | 2002-02-01 | 2005-06-08 | 诺沃挪第克公司 | 氨基烷基-取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺 |
| SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
| JP4595542B2 (ja) * | 2002-07-30 | 2010-12-08 | 萬有製薬株式会社 | ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
| US7601868B2 (en) | 2003-02-12 | 2009-10-13 | Takeda Pharmaceutical Company Limited | Amine derivative |
| US20060293298A1 (en) * | 2003-04-10 | 2006-12-28 | Bamford Mark J | Compounds |
| EP1706384A1 (en) | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Therapeutic agents i |
| GB0400193D0 (en) | 2004-01-07 | 2004-02-11 | Astrazeneca Ab | Therapeutic agents |
| US7241787B2 (en) * | 2004-01-25 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments |
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| CA2575081C (en) * | 2004-07-26 | 2013-05-07 | Eli Lilly And Company | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| JP5057982B2 (ja) | 2004-10-18 | 2012-10-24 | イーライ リリー アンド カンパニー | ヒスタミンh3受容体阻害剤、製造及び治療的使用 |
| DE602005009021D1 (de) | 2004-12-17 | 2008-09-25 | Lilly Co Eli | Neue mch-rezeptorantagonisten |
| EP1831194A4 (en) | 2004-12-21 | 2009-12-02 | Astrazeneca Ab | HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF |
| JP2006176443A (ja) | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
| CA2610671A1 (en) * | 2005-05-31 | 2006-12-07 | Astrazeneca Ab | Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders |
| JP2009501217A (ja) | 2005-07-15 | 2009-01-15 | アストラゼネカ アクチボラグ | 治療薬 |
| CN101400677A (zh) * | 2006-01-06 | 2009-04-01 | 阿斯利康(瑞典)有限公司 | 化合物 |
| AU2007275301A1 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
| JP2010501553A (ja) | 2006-08-18 | 2010-01-21 | アストラゼネカ アクチボラグ | Mchr1アンタゴニストとしてのチエノピリミジン−4−オン誘導体およびチエノピリダジン−7−オン誘導体 |
| EP2102208B1 (en) | 2006-12-05 | 2014-04-23 | Janssen Pharmaceutica NV | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases |
| EA015559B1 (ru) | 2006-12-14 | 2011-08-30 | Эли Лилли Энд Компани | ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH |
| EP2148931A2 (en) | 2007-04-17 | 2010-02-03 | Vertex Pharmaceuticals Incorporated | Drug discovery methods for aurora kinase inhibitors |
| ATE519738T1 (de) | 2007-08-22 | 2011-08-15 | Hoffmann La Roche | Pyrrolidinarylether als nk3-rezeptorantagonisten |
| ES2372332T3 (es) * | 2007-10-17 | 2012-01-18 | Sanofi | N-fenil-bipirrolidina carboxamidas sustituidas y su uso terapéutico. |
| JPWO2009154132A1 (ja) * | 2008-06-19 | 2011-12-01 | Msd株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
-
2010
- 2010-04-28 SA SA110310332A patent/SA110310332B1/ar unknown
- 2010-04-29 CN CN201410183568.1A patent/CN103936751A/zh active Pending
- 2010-04-29 HR HRP20160128TT patent/HRP20160128T1/hr unknown
- 2010-04-29 JP JP2012507821A patent/JP5763052B2/ja not_active Expired - Fee Related
- 2010-04-29 DK DK10718670.2T patent/DK2424870T3/en active
- 2010-04-29 ES ES10718670.2T patent/ES2562831T3/es active Active
- 2010-04-29 HU HUE10718670A patent/HUE026856T2/en unknown
- 2010-04-29 PL PL10718670T patent/PL2424870T3/pl unknown
- 2010-04-29 MX MX2011011618A patent/MX2011011618A/es active IP Right Grant
- 2010-04-29 CN CN201080031068.6A patent/CN102459279B/zh not_active Expired - Fee Related
- 2010-04-29 WO PCT/GB2010/050698 patent/WO2010125390A1/en not_active Ceased
- 2010-04-29 BR BRPI1014387A patent/BRPI1014387A2/pt not_active IP Right Cessation
- 2010-04-29 PT PT107186702T patent/PT2424870E/pt unknown
- 2010-04-29 SI SI201031124T patent/SI2424870T1/sl unknown
- 2010-04-29 CA CA2759230A patent/CA2759230A1/en not_active Abandoned
- 2010-04-29 KR KR1020117028655A patent/KR20120023044A/ko not_active Ceased
- 2010-04-29 EP EP10718670.2A patent/EP2424870B1/en not_active Not-in-force
- 2010-04-29 TW TW099113722A patent/TW201100433A/zh unknown
- 2010-04-29 AU AU2010243341A patent/AU2010243341B2/en not_active Ceased
- 2010-04-29 RU RU2011147751/04A patent/RU2526055C2/ru not_active IP Right Cessation
- 2010-04-30 AR ARP100101476A patent/AR076516A1/es not_active Application Discontinuation
- 2010-04-30 US US12/771,594 patent/US8110566B2/en not_active Expired - Fee Related
- 2010-04-30 UY UY0001032593A patent/UY32593A/es not_active Application Discontinuation
-
2016
- 2016-02-11 SM SM201600041T patent/SMT201600041B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010125390A1 (en) | 2010-11-04 |
| HUE026856T2 (en) | 2016-07-28 |
| US20100280000A1 (en) | 2010-11-04 |
| ES2562831T3 (es) | 2016-03-08 |
| KR20120023044A (ko) | 2012-03-12 |
| UY32593A (es) | 2010-11-30 |
| MX2011011618A (es) | 2011-11-18 |
| AU2010243341B2 (en) | 2014-02-13 |
| JP5763052B2 (ja) | 2015-08-12 |
| CN102459279B (zh) | 2014-06-25 |
| EP2424870B1 (en) | 2015-12-16 |
| CN102459279A (zh) | 2012-05-16 |
| CA2759230A1 (en) | 2010-11-04 |
| BRPI1014387A2 (pt) | 2017-06-06 |
| TW201100433A (en) | 2011-01-01 |
| SA110310332B1 (ar) | 2013-12-10 |
| SI2424870T1 (sl) | 2016-03-31 |
| CN103936751A (zh) | 2014-07-23 |
| AR076516A1 (es) | 2011-06-15 |
| EP2424870A1 (en) | 2012-03-07 |
| PT2424870E (pt) | 2016-03-17 |
| AU2010243341A1 (en) | 2011-11-03 |
| RU2526055C2 (ru) | 2014-08-20 |
| DK2424870T3 (en) | 2016-02-15 |
| SMT201600041B (it) | 2016-02-25 |
| JP2012525365A (ja) | 2012-10-22 |
| HRP20160128T1 (hr) | 2016-02-26 |
| US8110566B2 (en) | 2012-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0811304D0 (en) | Therapeutic agents | |
| GB0908957D0 (en) | Therapeutic agents | |
| GB0811643D0 (en) | New therapeutic agents | |
| GB0819593D0 (en) | Therapeutic agents | |
| IL201235A0 (en) | Therapeutic agents | |
| GB0921075D0 (en) | Novel combination of the therapeutic agents | |
| GB0801081D0 (en) | Therapeutic agents | |
| GB0821693D0 (en) | Therapeutic agents | |
| GB0723747D0 (en) | Therapeutic agents | |
| GB0801080D0 (en) | Therapeutic agents | |
| GB0812309D0 (en) | Therapeutic agents | |
| GB0805818D0 (en) | Therapeutic agents | |
| GB0724340D0 (en) | Novel Therapeutic Agents | |
| PT2424870E (pt) | Agentes terapêuticos 713 | |
| EP2454276A4 (en) | THERAPEUTIC AGENTS | |
| GB0723748D0 (en) | Therapeutic agents | |
| GB0910493D0 (en) | Therapeutic agents | |
| GB0811715D0 (en) | Therapeutic agents | |
| GB0911965D0 (en) | Therapeutic agents | |
| GB0919819D0 (en) | Therapeutic agents | |
| GB0914533D0 (en) | Therapeutic agents | |
| GB0903949D0 (en) | Therapeutic agents | |
| GB0907971D0 (en) | Therapeutic agents | |
| GB0915586D0 (en) | Therapeutic agents | |
| GB0919820D0 (en) | Therapeutic agents |